

Energetics and Clinical Factors for the Time Required to Walk 400 Meters The Study of Muscle, Mobility and Aging (SOMMA)

Steven R. Cummings, MD^{1,2}, Li-Yung Lui, MA, MS¹, Nancy W. Glynn, PhD³, Theresa Mau, PhD^{1,2}, Peggy M. Cawthon, PhD, MPH^{1,2}, Stephen B. Kritchevsky⁴, Paul M. Coen, PhD⁴, Bret Goodpaster, PhD⁴, David J. Marcinek, PhD⁶, Russell T. Hepple, PhD⁷, Sheena Patel, MPH¹, Anne B. Newman, MD, MPH³

Affiliations

1. San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, California
2. Department of Epidemiology and Biostatistics, University of California, San Francisco, California.
3. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
4. Department of Internal Medicine-Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
5. AdventHealth, Translational Research Institute, Orlando, Florida.
6. Department of Radiology, University of Washington, Seattle, Washington.
7. Department of Physical Therapy, University of Florida, Gainesville, Florida.

Corresponding author

Steven Cummings, MD

San Francisco Coordinating Center

Mission Hall: Box #0560

550-16th Street, 2nd Floor

San Francisco, CA 94143

steven.cummings@ucsf.edu

415-203-2864

Word counts

Abstract: 285

Main text: 3453

Funding sources

The Study of Muscle, Mobility and Aging is supported by funding from the National Institute on Aging, grant number AG059416. Study infrastructure support was funded in part by NIA Claude D. Pepper Older American Independence Centers at University of Pittsburgh (P30AG024827) and Wake Forest University (P30AG021332) and the Clinical and Translational Science Institutes, funded by the National Center for Advancing Translational Science, at Wake Forest University (UL1 OTR001420).

Running head

Time to Walk 400 meters

Abstract

Background: Walking slows with aging often leading to mobility disability. Mitochondrial energetics has been found to influence gait speed over short distances. Additionally, walking is a complex activity but few clinical factors that may influence walk time have been studied.

Methods: We examined 879 participants ≥ 70 years and measured the time to walk 400m. We tested the hypothesis that decreased mitochondrial energetics by respirometry in muscle biopsies and magnetic resonance spectroscopy in the thigh, is associated with longer time to walk 400m. We also used cardiopulmonary exercise testing to assess the energetic costs of walking: maximum oxygen consumption (VO_{2peak}) and energy cost-capacity (the ratio of VO_2 at a slow speed to VO_{2peak}). In addition, we tested the hypothesis that selected clinical factors would also be associated with 400m walk time.

Results: Lower Max OXPHOS was associated with longer walk time and the association was explained by the energetics costs of walking, leg power and weight. Additionally, a multivariate model revealed that longer walk time was also significantly associated with lower VO_{2peak} , greater cost-capacity ratio, weaker leg power, heavier weight, hip and knee stiffness, peripheral neuropathy, greater perceived exertion while walking slowly, greater physical fatigability, less moderate-to-vigorous exercise, less sedentary time and anemia. Significant associations between age, sex, muscle mass, and peripheral artery disease with 400m walk time were explained by other clinical and physiologic factors.

Conclusions: Lower mitochondrial energetics is associated with needing more time to walk 400m. This supports the value of developing interventions to improve mitochondrial energetics. Additionally, doing more moderate-to-vigorous exercise, increasing leg power, reducing weight, treating hip and knee stiffness, and screening for and treating anemia may reduce the time required to walk 400m and reduce the risk of mobility disability.

Mobility, the ability to walk far enough fast enough to conduct activities of daily living, is essential for maintaining independence. The prevalence of mobility disability defined as the inability to walk ½ mile or climb a flight of steps increased from 25.9% of women and 16.7% of men aged 70-74 years reported, to 50.5% of women and 35.3% of men aged 80-84.¹ Walking 400m is equivalent to walking 2 to 3 blocks and walking that distance too slowly may limit the ability to shop for oneself or cross intersections within the cycle of changing lights. Several studies have shown that slower 400-meter (400m) walk speed or inability to complete a 400m walk is strongly associated with progression to more advanced disability and total as well as cardiovascular mortality in older adults.²⁻⁴ The 6-minute walk test, a similar test that sets the time and measures distance,^{5,6} has been associated with mortality and cardiovascular events in cohort studies,⁷ and in patients with heart failure, chronic obstructive pulmonary disease, and peripheral artery disease.⁸⁻¹⁰

Mobility disability, requiring more than 15 minutes to walk 400m, has been the outcome for several large clinical trials.¹¹ In the Lifestyle Intervention and Independence for Elders (LIFE) Study, a physical activity program reduced the incidence of major mobility disability, defined as the inability to walk 400m, by 18% from 35.5% to 30.1% after 2.6 years.¹² The Sarcopenia and Physical fRailty IN older people: multi-component Treatment strategies (SPRINTT) project had interventions which reduced major mobility disability by 23%.¹³ While these findings are promising, stronger interventions are needed and might involve additional interventions on other factors that contribute to a long 400-meter walk time.^{14,15}

Walking is a complex activity.¹⁶ Preventing decline in mobility requires a better understanding of factors that contribute to the ability to walk 400m. Multimorbidity and lack of physical activity are major correlates of mobility disability¹⁷⁻¹⁹ but do not explain the steep increase in incidence of mobility disability with age.^{1,20}

Previous studies suggest that the decline of muscle mitochondrial function that occurs with aging may contribute to the decline in mobility.^{21–24} Most have used magnetic resonance spectroscopy (MRS) to estimate the capacity of mitochondria in thigh muscle to generate adenosine triphosphate (ATP).²⁴ Few have also directly measured mitochondrial energetics in muscle biopsies to determine the role of muscle mitochondria in mobility.^{22,25} The energy required to walk at one's usual pace increases with aging after the seventh decade and has been associated with slow gait speed over short distances, e.g. 6 meters.²⁶

Few other potential correlates of gait speed have been studied.¹⁶ A few studies of gait speed over 3 to 20 m found associations that include leg extension force, height, body mass index, balance, sedentary behavior, and chronic obstructive lung and cardiovascular disease. Loss of skeletal muscle mass has been shown to play a role as well.²⁷ It has been proposed that gait mechanics and stiffness of tendons around lower extremity joints might be important.¹⁶

We tested the hypothesis that muscle mitochondrial energetics would be an important correlate of the time it takes an individual to walk 400m. As walking 400m is a complex activity we also tested the hypothesis and systematically assessed many other factors that would contribute to the 400m walk time. We analyzed these potential correlates of the 400m walk time in the Study of Muscle, Mobility and Aging (SOMMA), a cohort study of the biological determinants of mobility.

Methods

SOMMA is a cohort study of 879 individuals aged 70 or older who were recruited by field centers at University of Pittsburgh and Wake Forest University School of Medicine. A description of the design and methods of SOMMA has been published.²⁸ All participants provided written, informed consent, and the Western IRB-Copernicus Group (WCG) Institutional Review Board approved the SOMMA (WCGIRB #20180764).

Participants must have been able to complete the 400-meter walk; those who appeared as they might not be able to complete the 400m walk at the in-person screening visit completed a short distance walk (4 meters) to ensure their walking speed was $\geq 0.6\text{m/s}$. The 400m walk was conducted at the participant's usual or preferred pace for 10 laps around a 40-meter course without any assistive device other than a straight cane. The total time (seconds) to walk 400m included the rest time if the participant stopped walking during the test.

To assess mitochondrial energetics, we performed high resolution respirometry on permeabilized muscle fibers from percutaneous muscle biopsies from the vastus lateralis.²² Methods for mitochondrial respirometry to assess the activity of mitochondrial electron transport system have been published.²⁵ This study uses maximal oxidative phosphorylation (OXPHOS) supported by complex I- and II-linked carbohydrates (Max OXPHOS) as a measure of *ex vivo* muscle mitochondrial energetics. In addition, we used ³¹Phosphorous magnetic resonance spectroscopy (³¹P MRS) to measure of *in vivo* muscle mitochondrial energetics. It measures the rate of phosphocreatine (PCr) recovery after an acute bout of knee extensor exercise to estimate the maximal production of adenosine triphosphate (ATP_{max}).²⁹

We defined several domains of factors, besides mitochondrial energetics, that may contribute to the time required to complete the 400m walk. The domains were cardiorespiratory fitness and energetic cost of walking, body stature and composition, muscle mass, strength and power, blood flow, oxygen delivery, cardiopulmonary disease, perceived fatigability and exertion, depressive symptoms, cognitive performance, neurologic conditions, joint symptoms, usual physical activity, vision, general health and medical conditions, health habits, and socioeconomic status. For each domain, we measured candidate variables that reflect the effect of the domains on time to walk 400m.²⁸

To assess the energetic costs of walking, participants completed a three-stage cardiopulmonary treadmill exercise test (CPET) using a symptom-limited modified Balke or manual protocol

during which the volume of oxygen (VO_2) uptake was measured.³⁰ Participants began the VO_{2peak} test at preferred walking speed as the treadmill speed (0.5 mph) and grade (2.5%) were incrementally increased until participants reach a respiratory exchange ratio (RER) ≥ 1.05 and self-reported Borg Rating of Perceived Exertion (RPE) was ≥ 17 .³¹ VO_{2peak} (mL/min) was defined as the highest 30-second average oxygen consumption over the course of the test. The energy cost of walking was calculated as the average VO_2 mL/min while walking at a steady slow speed: 1.5 mph for 5 min at zero grade. Energy cost-to-capacity ratio is the proportion of VO_{2peak} required to walk at the steady 1.5 mph pace (the ratio of VO_2 mL/min at a steady pace divided by VO_{2peak} mL/min).³²

Weight was measured using a balance beam or digital scales. Leg extension strength was assessed by a one repetition max (1RM) on a Keiser Air 420 exercise machine, and peak power was measured across the 40-70% range of leg extension.³³ Whole body skeletal muscle mass was measured by D_3 -creatine dilution (D_3Cr).^{34,35} A whole body magnetic resonance (MR) scan included fat-free thigh muscle volume.³⁶

To assess impaired delivery of oxygen to leg muscles, systolic blood pressure was measured by Doppler in the arm (brachial artery) and ankle (posterior tibial artery) on both sides and peripheral artery disease was classified as present if the ankle to brachial artery ratio or index (ABI) was less than 1.0 in either leg.^{37,38} Anemia was defined as hemoglobin $< 13.5\%$ for men and $< 12\%$ for women. We measured perceived fatigability by the Pittsburgh Fatigability Scale (PFS, scale 0-50, higher = greater fatigability) and Borg RPE Scale (RPE Fatigability, scale 6-20, higher exertion = greater fatigability) at the end of the 5 min walk.^{39,40}

We assessed peripheral sensory neuropathy by reduced touch sensation by the ability to feel fine filaments pressed against the great toe.⁴¹ Joint stiffness was assessed as self-report of stiffness in the hip or knee that made it difficult to walk often or always in the past 7 days. Physical activity was assessed using a wrist-worn ActiGraph GT9X for 7-full days and we assessed the time spent in moderate-to-vigorous physical activity (MVPA) (minutes/day).^{42,43}

Participants concurrently wore an activPal device on the thigh to characterize sedentary time (minutes/day) and total daily step count. General health status and medical history was assessed by self-reported diagnosis of common medical conditions. Methods for other examinations are described in the Supplement.

Statistical Methods

Linear regression was used in age-adjusted analyses to analyze the association of each variable with 400m walk time. We then used a series of forward stepwise regression models using a P-value of 0.1, to select the final multivariate model to identify the correlates of 400m walk time. Lastly, we used multiple imputation by fully conditional specification method to account for missing data (Supplemental Table 1). The results are expressed in seconds of walk time per SD or unit of each potential correlate or the equivalent beta coefficients.

We expected that many factors, such as mitochondrial energetics, would influence 400m walk time by their effect on other assessments, such as the energy cost of walking and may, therefore, not appear in the multivariable model. Thus, we systematically analyzed how the association of muscle mitochondrial energetics (Max OXPHOS) with 400m walk time was explained by VO_2 peak, the ratio of energy cost-capacity, and leg power by adding them individually and then together to the model between Max OXPHOS and 400m walk time.

Based on expert judgement and prior evidence about factors that influence walking speed, we analyzed other variables that were associated with age-adjusted 400m walk in bivariate analyses but were not included in the final stepwise model: age, sex, muscle mass and peripheral artery disease with walk time. As with the analysis of Max OXPHOS, we started with the association of that factor with 400m walk time, then adjusted for variables from the multivariable model that may at least partially account for the association until the association was no longer statistically significant.

Results

Characteristics of the 879 participants are described in Table 1. Participants had no contraindications to MR, CT scans, or muscle biopsy and, at a screening visit, were able to walk at least 0.6 m/s. The participants were initially contacted and screened for eligibility by phone. Of those eligible for and attended a screening 80% were enrolled in the study (Supplemental Figure 1). Details of process and results of screening have been published.²⁸

About half of the cohort was between 70 and 74 years of age. The mean 400-meter walk time was 6 minutes, 36 seconds.

There were weak or no correlations between the measurements except for an expected correlation of Pearson's $r > 0.5$ between measurements of body mass, strength, power and weight with VO_{2peak} (Supplemental Figure 2). Most of the 53 variables that were significantly associated with walk time remained so after adjusting for age (Table 2).

In bivariate analyses, maximal muscle mitochondrial respiration during ATP production (Max OXPHOS) was strongly associated with 400m walk time: an additional 22.1 s (17.5, 26.8) for each SD decrement. The association between max OXPHOS, with 400m walk time was completely attenuated by adjustments for the energy cost-capacity ratio, leg power, cardiorespiratory fitness (VO_{2peak}) and weight (Table 3). This accounts for the fact that Max OXPHOS, did not appear in the multivariate model that included these variables. The association between ATP_{max} and 400m walk time was no longer significant after adjustment for a higher energy cost-capacity ratio and heavier weight. Furthermore, the association of *in vivo* ATP_{max} by ^{31}P MRS with walk time (beta coefficient=12.4, $P<0.001$) was completely attenuated by adjustment for Max OXPHOS measured *ex vivo* from the muscle biopsy (adjusted beta coefficient = 3.6, $p = 0.21$). Therefore, hereafter, 'mitochondrial energetics' refers to Max OXPHOS.

In the multivariate model a higher ratio of VO_2 at the slow walking speed to the VO_{2peak} (cost-capacity ratio) was associated with nearly 20 seconds longer per SD of the measurement, to complete the 400m walk (Table 4). In addition, a lower VO_{2peak} indicated a 9 second longer time, per SD, to walk 400m. Weaker leg power was associated with about 17 seconds slower time for each standard deviation (SD) decrement. Despite the greater leg power of heavier individuals, greater weight was associated with longer walk time—adding about 22 seconds for each 15 kg greater weight. Self-report of frequent or continuous stiffness in the hips or knees was associated with about 54 seconds longer time to walk 400m. Peripheral neuropathy by the monofilament test added 20 seconds to the walk time.

Greater perceived physical fatigability was also associated with slower time to walk 400m by 6.0 (1.9, 10.1) seconds. Every 2-unit increase on the 6–20-point Borg scale, during the last 3 of 5 minutes of walking at a slow speed was associated with 10 seconds longer to complete the walk. Less time spent in objectively measured habitual moderate to vigorous physical activity was associated with a 9-seconds longer walk time for each decrement of SD. Less time spent in a sedentary mode was also associated with longer time to complete the 400-meter walk in bivariate analyses. Anemia was associated with a longer time to complete the walk by 16 seconds.

Several factors that may be important for the 400-meter walk time and were significant in age-adjusted associations did not appear in the multivariate model. This suggested that their associations with walk time were accounted for by other measurements in multivariate model. Besides Max OXPHOS and ATPmax, we examined the factors that explained the associations for age, sex, muscle mass, and peripheral vascular disease (Table 3). The association of older age with longer walk time was explained by weaker leg power, a higher energy cost-to-capacity ratio, less time spent in moderate to vigorous physical activity, and the association of greater weight with walk time. The longer walk time in women than men was fully explained by weaker

leg power and the association of greater weight with slower walk time. Lower muscle mass by the D₃Cr assay has been associated with slower walking speed.²⁷ In this analysis, associations of lower muscle mass by D₃Cr or by thigh fat-free muscle volume with longer walk time were fully attenuated by adjustment for heavier weight, weaker leg power and lower VO₂peak. In accord with previous research, peripheral vascular disease assessed by an ankle-arm blood pressure ratio <1.0, was associated with longer walking time;⁴⁴ we found that the association was completely attenuated by weight, weaker leg power, lower VO₂peak, higher ratio of energy cost-to-capacity, and anemia.

Discussion

The results of this study support the hypothesis that, in older adults, decreased mitochondrial energetics is associated with a longer time required to walk 400m. Walking 400m is a complex activity, and the results also support the hypothesis that several clinical and physiologic factors, some that can be modified, also influence 400m walk time.

A few previous studies have reported correlations between muscle mitochondrial energetics by high resolution respirometry in muscle biopsies with 400m walk speed.^{21–23,45} Others have reported correlations between ATP_{max} by ³¹P MRS and slower walking speed.^{23,46,47} Our results suggest that the direct assessment of mitochondrial energetics in muscle biopsies is more strongly associated with 400m walk time than is in vivo ATP_{max}. Studies have also observed that increasing acquired mitochondrial DNA mutations is associated with slower walking speed.⁴⁸ These studies using several approaches to assess the function and integrity of mitochondria in muscle lend support to our finding that muscle mitochondrial energetics is strongly associated with the time needed to walk 400m. Thus, ongoing development of treatments that preserve or enhance mitochondrial energetics may improve mobility and reduce the risk of disability.

The influence of mitochondrial energetics (Max OXPHOS) on 400-meter walk time was explained by leg power, the ratio of energy cost-to-capacity, and VO_2 peak along with weight. This is consistent with our previous findings that mitochondrial energetics in leg skeletal muscle is associated with VO_2 peak, and with leg power.²⁵ Our results confirm that, as the energy required to walk slowly approaches the capacity to generate energy, the time required to walk 400m increases.

Several other factors also influenced walk time. Weaker leg power, which partly reflects lower mitochondrial energetics, also substantially increased the time required for the 400m walk.

Greater weight was associated with greater leg power, but this was countered by the greater energy required to move a heavier body, suggesting that weight loss may reduce 400m walk time. Hip and knee stiffness added nearly one minute to the time required to walk 400m.

Depending on the underlying cause, these symptoms might be improved by non-steroidal anti-inflammatory drugs or physical therapy. We discovered that reduced touch sensation—measured by monofilament testing, prolonged average walking speed by about 20 seconds, suggesting that sensation is important for walking. As expected, a reduced capacity to generate energy and greater energy cost of walking resulted in a greater sense of exertion from walking slowly, as measured by the Borg Scale of perceived exertion during walking. The association of higher levels of physical fatigability during usual activity by the Pittsburgh scale indicates greater whole-body vulnerability to fatigability during standardized activities and might also reflect lower mitochondrial energetics during usual activities. It has also been shown that greater fatigability predicts greater risk of functional decline and mortality.^{49,50}

The association between habitual moderate-to-vigorous physical activities and 400m walk time supports promotion of regular moderate and vigorous physical activity to reduce the risk of mobility and maintain independence with aging.⁴⁹ This result is consistent with the results of LIFE Study randomized trial that found that a structured, moderate-intensity physical activity

program reduced the risk of major mobility disability defined as an inability to walk 400m within 15 minutes.¹² The association between less sedentary time and longer walk time was counterintuitive with no apparent reason why more sedentary time in usual activities would have a beneficial effect on time to walk 400m.

Anemia was associated with about 15 seconds longer time, presumably by limiting the supply of oxygen to muscle indicating that treatment of anemia might improve mobility. This suggests that screening for and treating anemia might reduce the time required to walk 400m and forestall the development of mobility disability.⁴⁴

It appeared that needing more time to walk 400m with aging may be at least partly attributable to decreasing leg power, a greater energy cost-to-capacity ratio, spending less time spent in at least moderate physical activity. This suggests that decline in walking speed with aging might be at least partly ameliorated by increasing physical activity and forms of exercise that improve leg power. On average, women required more time to walk 400m and this was partly attributable to lower leg power. We found that an association between lower muscle mass and longer 400-meter walk time was explained by weaker leg power and lower VO_{2peak} . This suggests that increasing muscle mass might reduce the time required to walk 400m and reduce the risk of mobility disability.²⁷ Peripheral artery disease also reduces blood and oxygen supply to the legs, and we found that it was associated with longer 400-meter walk time that was accounted for by its effects on reduced VO_{2peak} and by weaker leg power.

This study has limitations. It is cross-sectional, based on baseline data from SOMMA. Longitudinal data would enable associations of change in some factors with change in time to walk 400m, and follow-up to identify predictors of mobility disability. However, this cross-sectional study has the advantage of associating the immediate concomitant influence of energetics and clinical factors with the present time to walk 400-meters.

SOMMA did not assess the central nervous system control of walking, the influence of impaired balance, nor the mechanics of walking.^{16,52} A small proportion of the population walked slowly, 0.6-0.8 m/s and individuals with very slow gait, <0.6 m/s, were not included. The prevalence of some conditions, such as stroke, heart disease, and severe peripheral artery disease, may have been too low to detect their impacts. While the racial composition of the study reflects that of the communities surrounding the field centers, there was insufficient power to study potential racial differences in correlates of walk time.

This study has several strengths. It is the first to use direct measurement of skeletal muscle mitochondrial energetics from biopsies and energetics of walking by cardiopulmonary exercise testing to show that the effects of mitochondrial energetics are substantially mediated by the energetics of walking and leg power. Our endpoint, the time to walk 400-meters, is important to many activities of daily living whereas previous studies assessed gait speed over shorter distances. Furthermore, SOMMA assesses a wide array of potential causes of a long 400-meter walk time in a large population that enabled this analysis to identify several independent and modifiable predictors of walk time.

Conclusion

The time older individuals require to walk 400m is associated with muscle mitochondrial energetics. Aerobic exercise improves mitochondrial energetics and the ongoing development of novel therapies that target mitochondria might yield treatments that improve mitochondrial energetics and delay mobility disability.⁵³ In addition, other factors that may be amenable to interventions also influence 400m walk time. Our results suggest that, for older patients, maintaining habitual moderate-to-vigorous exercise and promoting exercise that improves leg power, reducing weight, treatment of lower hip and knee stiffness, and screening for and treatment of anemia may reduce the time they require to walk 400m and might thereby reduce their risk of developing mobility disability.

References.

1. Leveille SG, Penninx BWJH, Melzer D, Izmirlian G, Guralnik JM. Sex differences in the prevalence of mobility disability in old age: The dynamics of incidence, recovery, and mortality. *Journals Gerontol - Ser B Psychol Sci Soc Sci*. 2000;55(1). doi:10.1093/geronb/55.1.S41
2. Newman AB, Simonsick EM, Naydeck BL, et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. *Jama*. 2006;295(17):2018-2026. doi:10.1001/jama.295.17.2018
3. Vestergaard S, Patel K V., Bandinelli S, Ferrucci L, Guralnik JM. Characteristics of 400-meter walk test performance and subsequent mortality in older adults. *Rejuvenation Res*. 2009;12(3):177-184. doi:10.1089/rej.2009.0853
4. Simonsick EM, Newman AB, Visser M, et al. Mobility limitation in self-described well-functioning older adults: Importance of endurance walk testing. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2008;63(8):841-847. doi:10.1093/gerona/63.8.841
5. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure. *Can Med Assoc J*. 1985;132(8):919-921. /pmc/articles/PMC1345899/
6. Enright PL, McBurnie MA, Bittner V, et al. The 6-min walk test: A quick measure of functional status in elderly adults. *Chest*. 2003;123(2):387-398. doi:10.1378/chest.123.2.387
7. Yazdanyar A, Aziz MM, Enright PL, et al. Association between 6-minute walk test and all-cause mortality, coronary heart disease-specific mortality, and incident coronary heart disease. *J Aging Health*. 2014;26(4):583-599. doi:10.1177/0898264314525665
8. Beatty AL, Schiller NB, Whooley MA. Six-minute walk test as a prognostic tool in stable coronary heart disease: Data from the heart and soul study. *Arch Intern Med*. 2012;172(14):1096-1102. doi:10.1001/archinternmed.2012.2198
9. Spruit MA, Polkey MI, Celli B, et al. Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. *J Am Med Dir Assoc*. 2012;13(3):291-297. doi:10.1016/j.jamda.2011.06.009
10. McDermott MM, Greenland P, Tian L, et al. Association of 6-Minute Walk Performance and Physical Activity With Incident Ischemic Heart Disease Events and Stroke in Peripheral Artery Disease. *J Am Heart Assoc*. 2015;4(7):1-11. doi:10.1161/JAHA.115.001846
11. Espeland MA, Gill TM, Guralnik J, et al. Designing clinical trials of interventions for

- mobility disability: Results from the lifestyle interventions and independence for elders pilot (LIFE-P) trial. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2007;62(11):1237-1243. doi:10.1093/gerona/62.11.1237
12. Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: The LIFE study randomized clinical trial. *Jama*. 2014;311(23):2387-2396. doi:10.1001/jama.2014.5616
 13. Bernabei R, Landi F, Calvani R, et al. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). *Bmj*. 2022;377. doi:10.1136/bmj-2021-068788
 14. Correa-De-Araujo R, Bhasin S. Public Health Need, Molecular Targets, and Opportunities for the Accelerated Development of Function-Promoting Therapies: Proceedings of a National Institute on Aging Workshop. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2022;77(11):2227-2237. doi:10.1093/gerona/glac181
 15. Newman AB. The Epidemiology and Societal Impact of Aging-Related Functional Limitations: A Looming Public Health Crisis. *Journals Gerontol Ser A*. 2023;78(Supplement_1):4-7. doi:10.1093/gerona/glad021
 16. Boyer KA, Hayes KL, Umberger BR, et al. Age-related changes in gait biomechanics and their impact on the metabolic cost of walking: Report from a National Institute on Aging workshop. *Exp Gerontol*. 2023;173. doi:10.1016/j.exger.2023.112102
 17. Newman AB, Haggerty CL, Kritchevsky SB, Nevitt MC, Simonsick EM. Walking performance and cardiovascular response: Associations with age and morbidity - The health, aging and body composition study. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2003;58(8):715-720. doi:10.1093/gerona/58.8.m715
 18. Lange-Maia BS, Strotmeyer ES, Harris TB, et al. Physical activity and change in long distance corridor walk performance in the health, aging, and body composition study. *J Am Geriatr Soc*. 2015;63(7):1348-1354. doi:10.1111/jgs.13487
 19. Beauchamp MK, Leveille SG, Patel K V., et al. What physical attributes underlie self-reported vs. observed ability to walk 400 m in later life?: An analysis from the InCHIANTI study. *Am J Phys Med Rehabil*. 2014;93(5):396-404. doi:10.1097/PHM.0000000000000034
 20. Chang M, Cohen-Mansfield J, Ferrucci L, et al. Incidence of loss of ability to walk 400 meters in a functionally limited older population. *J Am Geriatr Soc*. 2004;52(12):2094-2098. doi:10.1111/j.1532-5415.2004.52570.x
 21. Lewsey SC, Weiss K, Schär M, et al. Exercise intolerance and rapid skeletal muscle

- energetic decline in human age-associated frailty. *JCI Insight*. 2020;5(20):1-15.
doi:10.1172/jci.insight.141246
22. Coen PM, Jubrias SA, Distefano G, et al. Skeletal muscle mitochondrial energetics are associated with maximal aerobic capacity and walking speed in older adults. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2013;68(4):447-455. doi:10.1093/gerona/gls196
 23. Choi S, Reiter DA, Shardell M, et al. 31P magnetic resonance spectroscopy assessment of muscle bioenergetics as a predictor of gait speed in the Baltimore longitudinal study of aging. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2016;71(12):1638-1645.
doi:10.1093/gerona/glw059
 24. Tian Q, Lee PR, Walker KA, Ferrucci L. Energizing Mitochondria to Prevent Mobility Loss in Aging: Rationale and Hypotheses. *Exerc Sport Sci Rev*. 2023;51(3):96-102.
doi:10.1249/jes.0000000000000315
 25. Mau T, Lui LY, Distefano G, et al. Mitochondrial Energetics in Skeletal Muscle Are Associated With Leg Power and Cardiorespiratory Fitness in the Study of Muscle, Mobility and Aging. *Journals Gerontol Ser A*. 2022;78(8):1367-1375.
doi:10.1093/gerona/glac238
 26. Schrack JA, Zipunnikov V, Simonsick EM, Studenski S, Ferrucci L. Rising energetic cost of walking predicts gait speed decline with aging. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2016;71(7):947-953. doi:10.1093/gerona/glw002
 27. Cawthon PM, Orwoll ES, Peters KE, et al. Strong relation between muscle mass determined by d3-creatine dilution, physical performance, and incidence of falls and mobility limitations in a prospective cohort of older men. *Journals Gerontol - Ser A Biol Sci Med Sci*. 2019;74(6):844-852. doi:10.1093/gerona/gly129
 28. Cummings SR, Newman AB, Coen PM, et al. The Study of Muscle, Mobility and Aging (SOMMA): A Unique Cohort Study About the Cellular Biology of Aging and Age-related Loss of Mobility. *Journals Gerontol Ser A*. Published online February 9, 2023.
doi:10.1093/gerona/glad052
 29. Amara CE, Marcinek DJ, Shankland EG, Schenkman KA, Arakaki LSL, Conley KE. Mitochondrial function in vivo: Spectroscopy provides window on cellular energetics. *Methods*. 2008;46(4):312-318. doi:10.1016/j.ymeth.2008.10.001
 30. Balady GJ, Arena R, Sietsema K, et al. Clinician's guide to cardiopulmonary exercise testing in adults: A scientific statement from the American heart association. *Circulation*. 2010;122(2):191-225. doi:10.1161/CIR.0b013e3181e52e69
 31. Borg GAV. Psychophysical bases of perceived exertion. *Plast Reconstr Surg*.

- 1954;14(5):377-381. <https://pubmed-ncbi-nlm-nih-gov.ucsf.idm.oclc.org/7154893/>
32. Schrack JA, Simonsick EM, Ferrucci L. The relationship of the energetic cost of slow walking and peak energy expenditure to gait speed in mid-to-late life. *Am J Phys Med Rehabil.* 2013;92(1):28-35. doi:10.1097/PHM.0b013e3182644165
 33. Winger ME, Caserotti P, Ward RE, et al. Jump power, leg press power, leg strength and grip strength differentially associated with physical performance: The Developmental Epidemiologic Cohort Study (DECOS). *Exp Gerontol.* 2021;145(August 2020):111172. doi:10.1016/j.exger.2020.111172
 34. Clark R V., Walker AC, O'Connor-Semmes RL, et al. Total body skeletal muscle mass: Estimation by creatine (methyl-d3) dilution in humans. *J Appl Physiol.* 2014;116(12):1605-1613. doi:10.1152/jappphysiol.00045.2014
 35. Shankaran M, Czerwieniec G, Fessler C, et al. Dilution of oral D 3 -Creatine to measure creatine pool size and estimate skeletal muscle mass: development of a correction algorithm. *J Cachexia Sarcopenia Muscle.* 2018;9(3):540-546. doi:10.1002/jcsm.12278
 36. Linge J, Borga M, West J, et al. Body Composition Profiling in the UK Biobank Imaging Study. *Obesity.* 2018;26(11):1785-1795. doi:10.1002/oby.22210
 37. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. *Circulation.* 1993;88(3):837-845. doi:10.1161/01.CIR.88.3.837
 38. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. *Arterioscler Thromb Vasc Biol.* 1999;19(3):538-545. doi:10.1161/01.ATV.19.3.538
 39. Glynn NW, Santanasto AJ, Simonsick EM, et al. The Pittsburgh fatigability scale for older adults: Development and validation. *J Am Geriatr Soc.* 2015;63(1):130-135. doi:10.1111/jgs.13191
 40. Simonsick EM, Schrack JA, Glynn NW, Ferrucci L. Assessing fatigability in mobility-intact older adults. *J Am Geriatr Soc.* 2014;62(2):347-351. doi:10.1111/jgs.12638
 41. Strotmeyer ES, De Rekeneire N, Schwartz A V., et al. The relationship of reduced peripheral nerve function and diabetes with physical performance in older white and black adults: The health, aging, and body composition (Health ABC) study. *Diabetes Care.* 2008;31(9):1767-1772. doi:10.2337/dc08-0433
 42. Arguello D, Andersen K, Morton A, Freedson PS, Intille SS, John D. Validity of proximity sensor-based wear-time detection using the ActiGraph GT9X. *J Sports Sci.* 2018;36(13):1502-1507. doi:10.1080/02640414.2017.1398891

43. Rhudy MB, Dreisbach SB, Moran MD, Ruggiero MJ, Veerabhadrapa P. Cut points of the Actigraph GT9X for moderate and vigorous intensity physical activity at four different wear locations. *J Sports Sci.* 2020;38(5):503-510. doi:10.1080/02640414.2019.1707956
44. McDermott MM, Liu K, Ferrucci L, et al. Decline in functional performance predicts later increased mobility loss and mortality in peripheral arterial disease. *J Am Coll Cardiol.* 2011;57(8):962-970. doi:10.1016/j.jacc.2010.09.053
45. Tyrrell DJ, Bharadwaj MS, Van Horn CG, Kritchevsky SB, Nicklas BJ, Molina AJA. Spirometric Profiling of Muscle Mitochondria and Blood Cells Are Associated With Differences in Gait Speed Among Community-Dwelling Older Adults. *Journals Gerontol - Ser A Biol Sci Med Sci.* 2015;70(11):1394-1399. doi:10.1093/gerona/glu096
46. Tian Q, Mitchell BA, Zampino M, Fishbein KW, Spencer RG, Ferrucci L. Muscle mitochondrial energetics predicts mobility decline in well-functioning older adults: The baltimore longitudinal study of aging. *Aging Cell.* 2022;21(2). doi:10.1111/accel.13552
47. Santanasto AJ, Coen PM, Glynn NW, et al. The relationship between mitochondrial function and walking performance in older adults with a wide range of physical function. *Exp Gerontol.* 2016;81:1-7. doi:10.1016/j.exger.2016.04.002
48. Manini TM, Buford TW, Kairalla JA, et al. Meta-analysis identifies mitochondrial DNA sequence variants associated with walking speed. *GeroScience.* 2018;40(5-6):497-511. doi:10.1007/s11357-018-0043-x
49. Simonsick EM, Schrack JA, Santanasto AJ, Studenski SA, Ferrucci L, Glynn NW. Pittsburgh Fatigability Scale: One-Page Predictor of Mobility Decline in Mobility-Intact Older Adults. *J Am Geriatr Soc.* 2018;66(11):2092-2096. doi:10.1111/jgs.15531
50. Glynn NW, Gmelin T, Renner SW, et al. Perceived Physical Fatigability Predicts All-Cause Mortality in Older Adults. *Journals Gerontol - Ser A Biol Sci Med Sci.* 2022;77(4):837-841. doi:10.1093/gerona/glab374
51. Lange-Maia BS, Newman AB, Cauley JA, et al. Sensorimotor peripheral nerve function and the longitudinal relationship with endurance walking in the health, aging and body composition study. *Arch Phys Med Rehabil.* 2016;97(1):45-52. doi:10.1016/j.apmr.2015.08.423
52. Brown C, Simonsick E, Schrack J, Ferrucci L. Impact of balance on the energetic cost of walking and gait speed. *J Am Geriatr Soc.* Published online 2023. doi:10.1111/jgs.18521
53. Murphy MP, Hartley RC. Mitochondria as a therapeutic target for common pathologies. *Nat Rev Drug Discov.* 2018;17(12):865-886. doi:10.1038/nrd.2018.174

Supplemental Figure S1. Flow chart of the enrollment process for SOMMA.

Supplemental Figure S2. Heat map of correlations between potential determinants of 400m walking speed.

Supplemental Table S1. Selected characteristics of the SOMMA cohort with number of missing

Supplemental Table S2. Abbreviations and definitions for the heat map

Supplemental text: Assessment methods

Acknowledgements – potential conflicts of interest

Dr. Cummings: consultant to BioAge

Dr. Cawthon: consultant to BioAge and consultant to Myocorp and owns stock in Myocorp

LL: none

NG: none

PMC: consultant to BioAge and consultant to Myocorp and owns stock in Myocorp

SBK: none

PC: none

BG: none

DJM: none

RTH: none

SP: none

ABN: none

Author contributions

Steven R. Cummings	Conceived the analysis plan, wrote 1 st draft, made rounds of revisions, and wrote the final version
Li-Yung Lui	Did most of the statistical analyses, wrote the statistical analysis section and made edits and revisions to the text
Nancy W. Glynn	Made revisions on several rounds of review
Theresa Mau	Provided references and generated the reference list and made revisions and edits on the last 3 drafts
Peggy M. Cawthon	Wrote text on clinical examinations, muscle mass measurements and supplemental methods
Stephen B. Kritchevsky	Made revisions to early versions of the paper and oversaw the internal SOMMA review and approval of the paper
Paul M. Coen	Wrote sections describing muscle respirometry
Bret Goodpaster	Revised and approved sections regarding cardiopulmonary exercise testing
David J. Marcinek	Directed 31PMRS scanning and reviewed and edited the section on mitochondrial energetics
Russell T. Hepple	Directs SOMMA's muscle biology core. Made revisions on an early draft and reviewed and approved the final version
Sheena Patel	Conducted the first rounds of statistical analyses. Reviewed and approved the final version of the statistical analysis section
Anne B. Newman	Contributed potential predictors of 400-walk time. Wrote the 1 st draft of the Introduction and then parts of the Discussion. Made revisions on the last 3 versions of the manuscript

Sponsor's role: none

Table 1. Selected characteristics of the SOMMA cohort

Characteristic*	
Sex	N (%)
Men (%)	359 (40.8)
Women (%)	520 (59.2)
Race	N (%)
White (%)	745 (84.8)
Black (%)	116 (13.2)
American Indian/Alaskan native (%)	2 (0.2)
Asian (%)	6 (0.7)
Multiracial/Unknown (%)	10 (1.0)
Hispanic/Latino	9 (1.1)
Age, years (SD)	76.3 (5.0)
Age groups	N (%)
70-74	402 (45.7)
75-79	273 (31.1)
80-84	134 (15.2)
85+	70 (8.0)
400m walk time (min); mean (SD)	6.6 (1.2)
400m walk time groups (min)	N (%)
<6	308 (35.0)
6 –< 8	473 (53.8)
8 – 15	98 (11.2)
Weight (kg)	Mean (SD)
Men	84.8 (13.8)
Women	70.1 (13.0)
Body mass index (kg/m ²); mean (SD)	27.6 (4.6)
Peak leg power (Watts)	Mean (SD)
Men	479.8 (161.4)
Women	271.0 (84.8)
Time in moderate to vigorous activity (min/d); mean (SD)	186.5 (86.1)
Sedentary time excluding in-bed time (min/d); mean (SD)	619.1 (113.1)
MoCA Total score; mean (SD)	24.8 (2.9)
Anemia, N (%)	142 (16.4)
History of chronic obstructive pulmonary disease, N (%)	115 (13.1)
History of heart failure, N (%)	6 (0.7)
History of stroke, N (%)	21 (2.4)
History of diabetes, N (%)	131 (15.0)

History of a diagnosis of depression, N (%)	161 (18.4)
Current smoker, N (%)	25 (2.9)
Number of drinks in the past 12-month, N (%)	2.8 (4.5)
Ankle-arm blood pressure index (Lowest of Left and Right) < 1.0, N (%)	97 (12.0)
Peripheral neuropathy by monofilament test, N (%)	46 (5.3)
Often/always hip or knee stiffness, N (%)	14 (1.6)
Pittsburgh Fatigability Scale Physical score, mean (SD)	15.8 (8.7)
Rating of Perceived Exertion Fatigability at end of the steady speed test, mean (SD)	8.4 (1.9)
	mean (SD)
VO ₂ peak (volume of oxygen consumption) (mL/min)	1865.6
Men	(410.7)
Women	1287.0
	(248.9)
Energy cost-capacity ratio, mean (SD)	48.8 (12.6)
Maximal mitochondrial oxidative phosphorylation (pmol/(s*mg), mean (SD)	59.7 (18.5)

*N (%) for categorical variables and mean (SD) for continuous variable

Table 2. List of candidate factors and their bivariate associations with 400m walk time. The domain category is in bold.

Domain and measurement	Age-adjusted beta coefficient (95% CI) per SD	Age-adjusted p-value
Age* (years)	--	--
Sex*	23.0 (13.8, 32.2)	<0.0001
Race* (non-Hispanic White)	43.3 (30.5, 56.0)	<0.0001
Education (College graduate or post college)	17.2 (7.8, 26.7)	0.0004
Leg muscle energetics		
Complex I and II supported Maximal OXPHOS (pmol/(s*mg))	22.1 (17.5, 26.8)	<0.0001
ATP _{max} (mM/sec)	12.4 (7.7, 17.2)	<0.0001
Cardiorespiratory fitness and energetics of walking		
VO ₂ peak (volume of oxygen consumption) (mL/min)	19.1 (14.4, 23.8)	<0.0001
Energy Cost-Capacity Ratio (%)	37.7 (33.5, 41.9)	<0.0001
Body stature and composition		
Height (m)	10.8 (6.3, 15.4)	<0.0001
Weight (kg)	14.6 (2.3, 10.1)	<0.0001
Body mass index (kg/m ²)	25.8 (21.5, 30.1)	<0.0001
Mean Quadriceps Muscle Fat Infiltration (%)	27.3 (22.9, 31.6)	<0.0001
Total Adipose Tissue (vol, L)	24.5 (20.1, 28.9)	<0.0001
Muscle mass and strength		
D ₃ Cr Muscle mass (kg)	6.9 (2.0, 11.7)	0.0055
Total Thigh Fat Free Muscle (volume, L)	10.0 (5.2, 14.7)	<0.0001
Leg Power Test 1RM (kg)	17.3 (12.7, 21.9)	<0.0001
Peak Leg Power (Watts) from 40-70% of 1RM	18.9 (14.2, 23.7)	<0.0001
Blood flow, oxygen delivery, cardiopulmonary disease		
Ankle-Arm Blood Pressure (Lowest of Left and Right) < 1.0	34.3 (19.7, 48.9)	<0.0001
Anemia, (Hemoglobin (g/dL) <13.5 M, <12.0 F)	29.1 (16.7, 41.5)	<0.0001
Heart Failure	3.9 (-51.6, 59.4)	0.8903

Systolic Blood Pressure (mmHg)	2.9 (-1.7, 7.4)	0.2201
Diastolic Blood Pressure (mmHg)	4.5 (-0.1, 9.1)	0.0547
Chronic Obstructive Pulmonary Disease*	15.1 (1.6, 28.6)	0.0291
Perceived fatigability and exertion		
Pittsburgh Fatigability Scale Physical score, 0-50 (higher=greater fatigability)	24.3 (20.0, 28.7)	<0.0001
Pittsburgh Fatigability Scale Mental score, 0-50 (higher=greater fatigability)	16.1 (11.7, 20.6)	<0.0001
Ratings of Perceived Exertion (RPE) Fatigability at end of slow walking speed test, (6-20; higher=greater exertion)	27.3 (23.0, 31.6)	<0.0001
Ratings of Perceived Exertion (RPE) Fatigability at end of 400M walking test, (6-20 (higher=greater exertion)	21.9 (17.5, 26.2)	<0.0001
Depressive symptoms		
Center of Epidemiologic Studies Depression Scale (CESD-10) (0-30)	3.5 (2.2, 4.8)	<0.0001
Depression, self-report*	22.5 (10.8, 34.3)	0.0002
Cognitive performance		
Digit Symbol Substitution Test (number of correct boxes)	19.0 (14.4, 23.6)	<0.0001
Montreal Cognitive Assessment (MoCA) Total score (0-30)	7.5 (2.8, 12.2)	0.0017
Trails B: Total time (0-300 sec)	16.2 (11.5, 20.8)	<0.0001
Neurologic conditions		
Monofilament test result - normal	17.7 (-2.9, 38.2)	0.0924
Experienced numbness, loss of sensation - Intensity	27.4 (1.5, 53.2)	0.0385
History of stroke*	1.8 (-2.8, 6.4)	0.4447
Joint symptoms*		
Any pain in left or right hip or knee	21.6 (11.7, 31.5)	<0.0001
Any back pain after 400m walk (Pain level 1-10=yes, 0=no)	39.0 (23.1, 55.0)	<0.0001
Moderate/Severe/Extreme hip or knee stiffness today	46.4 (31.1, 61.7)	<0.0001
In the past 7 days, often/always joints stiffness	86.4 (50.4, 122.4)	<0.0001
Usual physical activity		
activPAL: Mean of Total sedentary time, excluding in-bed time (min/day)	5.4 (0.3, 10.5)	0.0376
activPAL: Mean of Total daily step count	23.0 (18.1, 27.9)	<0.0001

ActiGraph: Mean of Sum of total activity counts/min over 24hrs	14.6 (10.0, 19.2)	<0.0001
ActiGraph: Mean of Time spent in Moderate-to-vigorous physical activities (min/day)	16.2 (11.6, 20.8)	<0.0001
Vision		
Pelli Robson Vision: Log contrast sensitivity	5.4 (0.8, 10.1)	0.0229
Bailey Lovie Vision: Acuity 20/50 or worse	6.7 (-3.8, 17.2)	0.2136
General health and medical conditions		
Good/Very Good/Excellent*	39.3 (18.5, 60.1)	0.0002
Diabetes*	22.3 (9.6, 35.1)	0.0006
HbA1c \geq 6.5%	30.6 (15.8, 45.4)	0.0001
Red cell distribution width (%)	12.1 (7.5, 16.7)	<0.0001
Health habits		
Cigarette smoking status*	45.7 (18.4, 73.0)	0.0011
Average drinks per week in past 12 months*	9.6 (5.1, 14.2)	<0.0001
Number of prescription medications in the past 30 days*	15.0 (10.6, 19.5)	<0.0001
Socioeconomic status		
Financial Accounts/Wealth* (0-8)	16.5 (12.0, 21.0)	<0.0001

Beta coefficients represent seconds of walk time.

Notes. *self-reported history.

Abbreviations: D₃Cr: d3-creatine dilution; 1RM, 1-repetition max; ATP_{max}, maximal adenosine triphosphate; OXPHOS, oxidative phosphorylation; HbA1c, hemoglobin A1C.

Table 4. Multivariable model of measurements associated with a slower time to complete a 400m walk


Measurement	Unit or S.D.	Slower time (s) (95% CI) per unit or per SD*	p-value
Higher energy cost-capacity ratio	13.1%	19.9 (13.8, 26.0)	<.001
Lower VO ₂ peak	445.1 mL/min	9.3 (2.2, 16.4)	0.011
Weaker peak leg power	161.0 watts	17.2 (11.9, 22.6)	<.001
Greater weight	15 kg	21.5 (16.0, 27.0)	<.001
Frequent or constant hip or knee joint stiffness	1 (yes)	53.7 (24.6, 82.8)	<.001
Peripheral neuropathy by monofilaments	1 (abnormal)	20.2 (3.9, 36.4)	0.015
Greater perceived exertion at end of steady state walking test†	2 units	10.0 (5.3, 14.8)	<.001
Higher Pittsburgh Fatigability Scale Physical score	8.7 units	6.0 (1.9, 10.1)	0.004
Less time in moderate-to-vigorous activity min/d	88.5 minutes	8.7 (4.2, 13.2)	<.001
Less sedentary time minutes/d	127.3 min	9.2 (3.8, 14.5)	<.001
Anemia	1 (anemia)	15.6 (5.9, 25.3)	0.002

* Equivalent to the beta coefficient


† On the 6- to 20-point Borg scale

Supplements

Supplemental Figure S1. Flow chart of the enrollment process for SOMMA.



Supplemental Figure S2



*All bivariate correlations assessed here use variables expressed continuously, even if they were treated as ordinal variables in other analyses within this report.

Supplemental Table. Abbreviations and definitions for the heat map

Abbreviation	Variable description
Time_400M	400m walk time, s
Age	Age, yrs
Height	Height, m
Weight	Weight, kg
BMI	Body mass index, kg/m ²
QuadMuscle	Quadriceps muscle Fat Infiltration, %
Adiposity	Total Abdominal Adipose Tissue volume, L
MuscleMass	D3Cr Muscle mass, kg
FFM	Total thigh fat free muscle volume, L
Strength_1RM	Leg power test 1RM, kg
LegPower	Leg power peak, Watts
ATPmax	ATP _{max} , mM/sec
OXPHOS	Max OXPHOS _{CI+CIII} , pmol/(s*mg)
VO ₂ peak	VO ₂ peak, mL/min
EnergyRatio	Energy Cost-Capacity Ratio, %
ABI	Ankle-Arm Blood Index
Hgb	Hemoglobin, g/dL
SBP	Systolic blood pressure, mmHg
DBP	Diastolic blood pressure, mmHg
PhyFatig	Pittsburgh Fatigability Scale Physical score
MentalFatig	Pittsburgh Fatigability Scale Mental score
Borg_SS	Rating of Perceived Exertion at end of steady (1.5 mi/h) speed test
Borg_400M	Rating of Perceived Exertion at end of 400M walking test
DSST	Digit symbol substitution test
MoCA	Montreal Cognitive Assessment
TrailsB	Trails B test
CESD	Center for Epidemiologic Studies Depression Scale, 10-item
BackPN	Any back pain after 400M walk
LCS	Pelli Robson Vision: Log contrast sensitivity
SedenTime	Total sedentary time, minute/day
StepCount	Total daily step count
TotActivity	Total activity counts/minute
MVPATime	Time spent in moderate to vigorous physical activity, minute/day
HbA1C	HbA1C
RDW	Red cell distribution width, %
DrinkWeek	Alcohol, drinks/week
NumMed	Prescription medications (count)
Wealth	Financial accounts/wealth

Abbreviations. D3Cr, d3-creatine dilution; 1RM, 1-repetition max; ATP_{max}, maximal adenosine triphosphate; OXPHOS, oxidative phosphorylation; HbA1c, Hemoglobin A1c

Supplement: Assessment methods

Digit symbol substitution test (DSST) is a cognitive function measure of processing speed: in this pencil and paper test, the participant associates a series of symbols with corresponding numbers. Global cognitive function was by the Montreal Cognitive Assessment (MoCA) tool,¹ and executive function by the Trails B test.² Perceived physical and mental fatigability was captured using the validated 10-item Pittsburgh Fatigability Scale (PFS, 0-50, higher score equals greater fatigability).^{3,4} Body stature and composition were assessed stadiometers (height), digital scales (weight), whole body MRI analyzed by AMRA (total thigh muscle volume; muscle fat infiltration; abdominal adiposity as the sum of abdominal subcutaneous and visceral fat volume),⁵ D₃Cr muscle mass (by d3-creatine dilution),^{6,7} and body mass index was calculated as weight (kg) divided by height (m²). Reduced touch sensation by the ability to feel fine filaments pressed against the great toe was used to assess peripheral neuropathy.⁸ Contrast sensitivity and visual acuity were also assessed.^{9,10} General health was measured by self-reported health and analyzed as good/very good/excellent vs. lower rating. Self-reported health habits included smoking and alcohol use. Participants were instructed to bring in all prescription medications used in the past 30 days; clinic staff recoded the number brought into clinic. Participants reported the number of financial accounts they had as a marker of wealth. Ankle-arm blood pressure was measured to assess peripheral arterial disease.¹¹ Diastolic and systolic blood pressures were measured. Numbness was considered present if intensity of “numbness, loss of sensation, or a ‘dead’ feeling like an anesthetic, without prickling, in your feet or leg below the knees” in the past twenty-four hours was moderate or severe. Pain in the hip and knee was assessed using the Brief Pain Inventory administered on the day of (and before) the 400m walk assessment. A complete blood count was used to determine HbA1c and red cell distribution width.

References

1. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.* 2005;53(4):695-699. doi:10.1111/J.1532-5415.2005.53221.X
2. Reitan RM. Validity of the Trail Making Test As an Indicator of Organic Brain Damage. *Percept Mot Skills.* 1958;8(7):271. doi:10.2466/pms.8.7.271-276
3. Glynn NW, Santanasto AJ, Simonsick EM, et al. The Pittsburgh fatigability scale for older adults: Development and validation. *J Am Geriatr Soc.* 2015;63(1):130-135. doi:10.1111/jgs.13191
4. Renner SW, Bear TM, Brown PJ, et al. Validation of Perceived Mental Fatigability Using the Pittsburgh Fatigability Scale. *J Am Geriatr Soc.* 2021;69(5):1343-1348. doi:10.1111/jgs.17017
5. Linge J, Borga M, West J, et al. Body Composition Profiling in the UK Biobank Imaging Study. *Obesity.* 2018;26(11):1785-1795. doi:10.1002/oby.22210
6. Clark R V., Walker AC, O'Connor-Semmes RL, et al. Total body skeletal muscle mass: Estimation by creatine (methyl-d3) dilution in humans. *J Appl Physiol.* 2014;116(12):1605-1613. doi:10.1152/jappphysiol.00045.2014
7. Shankaran M, Czerwiec G, Fessler C, et al. Dilution of oral D 3 -Creatine to measure creatine pool size and estimate skeletal muscle mass: development of a correction algorithm. *J Cachexia Sarcopenia Muscle.* 2018;9(3):540-546. doi:10.1002/jcsm.12278
8. Strotmeyer ES, De Rekeneire N, Schwartz A V., et al. The relationship of reduced peripheral nerve function and diabetes with physical performance in older white and black adults: The health, aging, and body composition (Health ABC) study. *Diabetes Care.* 2008;31(9):1767-1772. doi:10.2337/dc08-0433
9. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. *Clin Vis Sci.* 1988;2(3):187-199.
10. Bailey IL, Lovie JE. New design principles for visual acuity letter charts. *Optom Vis Sci.* 1976;53(11):740-

745. doi:10.1097/00006324-197611000-00006
11. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. *Arterioscler Thromb Vasc Biol.* 1999;19(3):538-545. doi:10.1161/01.ATV.19.3.538

Supplemental Table S1. Selected characteristics of the SOMMA cohort with number of missing

Characteristic	Number of missing
Sex	0
Race	0
Hispanic/Latino	0
Age	0
400m walk time (sec)	0
Weight (kgs)	0
Body mass index (kg/m ²)	0
Peak leg power (Watts)	
Men	13
Women	23
Time in moderate to vigorous activity (min/d)	56
Sedentary time excluding in-bed time (min/d)	194
MoCA Total score	14
Anemia	15
History of chronic obstructive pulmonary disease	3
History of heart failure	3
History of stroke	3
History of diabetes	3
History of a diagnosis of depression	4
Current smoker	5
Number of drinks in the past 12 month	14
Ankle-arm blood pressure index (Lowest of Left and Right) < 1.0	69
Peripheral neuropathy by monofilament test	18
Often/always hip or knee stiffness	3
Pittsburgh Fatigability Scale Physical score	6
Ratings of Perceived Exertion Fatigability at end of the steady speed test	37
VO ₂ peak (volume of oxygen consumption) (mL/min)	
Men	17
Women	42
Energy cost-capacity Ratio	66
Maximal mitochondrial oxidative phosphorylation (pmol/(s*mg))	134